In:
Future Oncology, Future Medicine Ltd, Vol. 14, No. 4 ( 2018-02), p. 353-361
Abstract:
Aim: Ceritinib was evaluated within a compassionate use program of Italian patients. Patients & methods: 70 patients with anaplastic lymphoma kinase-positive crizotinib-refractory advanced non-small-cell lung cancer received ceritinib. Results: Overall response was 40.6%, median progression-free survival was 8.2 months and median survival was 15.5 months. Dose reduction due to treatment-related adverse events occurred in 50.8% of patients starting at 750 mg/day. No significantly different progression-free survival was observed between patients who underwent any time dose reduction (n = 38) versus those who remained on the recommended dose of 750 mg/day (n = 32; p = 0.07). Conclusion: The efficacy of ceritinib compassionate use program resembled that of clinical trials. Dose reductions and adjustments did not appear to negatively affect clinical outcome.
Type of Medium:
Online Resource
ISSN:
1479-6694
,
1744-8301
DOI:
10.2217/fon-2017-0441
Language:
English
Publisher:
Future Medicine Ltd
Publication Date:
2018
Bookmarklink